A transplant pharmacist looks at what azacitidine plus venetoclax’s event-free survival advantage over intensive chemotherapy means for induction selection, and why it doesn’t yet replace 7+3 or CPX-351.
Early germline BRCA testing identifies patients with metastatic pancreatic adenocarcinoma who can be considered for olaparib maintenance if their disease has not progressed after at least 16 weeks of first-line platinum chemotherapy.
In every practice setting, pharmacists can meet vaccine hesitancy with evidence, effective communication, and vetted resources that move patients toward “yes.”
A new US consensus on pancreatic enzyme replacement therapy in pancreatic cancer highlights how pharmacists can counsel patients on taking enzymes with food, check response early, and address barriers to filling the prescription.
Retail pharmacists use a quick checklist to spot risky antithrombotic duplicates, dosing mistakes, OTC interactions, and adherence gaps—helping prevent stroke and bleeding.